Acrux, KV Pharmaceutical deal

The companies expanded KV’s rights to use Acrux’s spray technology to include up to six new compounds. KV already markets Acrux’s EvaMist estradiol transdermal spray in the U.S. to treat moderate to severe vasomotor symptoms due to menopause. The expansion includes U.S. development and marketing rights to three preclinical compounds. Acrux will have rights elsewhere and may use data contained in KV’s FDA filings for regulatory filings in all other territories. Acrux is eligible for milestones and royalties, and KV would receive a share of licensing revenues from products in Acrux’s territories. ...